Vaxcyte, Inc.
NASDAQ:PCVXBiotechnology
+$1.94 today
- Market cap
- $9.26B
- Beta
- 1.24
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$6.78
Volume 1.13M
Average 1.44M
PCVX Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Vaxcyte, Inc.NASDAQ: PCVX
Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares grows in line with its trailing trend
Q2 FY2026 weighted avg shares of 144.49M shares rose 6.2% year over year, behind the +7.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +28.0% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +6.2% toward the trailing-twelve-month pace of +7.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 136.09M USD
- Year-over-year change
- +11.6%
- 4-year CAGR
- +27.2%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 136.09M | +11.6% |
| FY2024 | 2024-12-31 | 122M | +25.6% |
| FY2023 | 2023-12-31 | 97.16M | +49.8% |
| FY2022 | 2022-12-31 | 64.88M | +25.0% |
| FY2021 | 2021-12-31 | 51.92M | — |
Weighted Avg Shares vs competitors
How PCVX compares with its peers on the latest reported figures
- PCVX's LTM Jun 2026 weighted avg shares of 139.07M shares is the 7th highest of the 9 companies compared; the peer median is 279.2M shares.
- Its year-over-year change of +7.3% is the 3rd highest of 9, against a peer median of +2.7%.
- Over three fiscal years its annual growth of +28.0% compares with a peer median of +1.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | 5.69B | +0.3% | +0.4% | |
| LTM Jun 2026 | 2.01B | -1.4% | +0.2% | |
| LTM Sep 2026 | 1.03B | +20.6% | +32.0% | |
| LTM Sep 2026 | 396M | +2.3% | -0.4% | |
| LTM Mar 2026 | 162.41M | +3.2% | +27.5% | |
| LTM Mar 2026 | 140.99M | +3.1% | +1.5% | |
| LTM Jun 2026 | 139.07M | +7.3% | +28.0% | |
| LTM Mar 2026 | 83.89M | +18.5% | +13.4% | |
| LTM Mar 2026 | 27.53M | +1.8% | +1.2% | |
| Peer median (excluding PCVX) | 279.2M | +2.7% | +1.3% | |
Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 78.41M | 169.45M | 332.34M | 476.64M | 794.31M |
| Selling, General & Admin | 25.26M | 39.81M | 60.7M | 92.9M | 129.37M |
| Operating Expenses | 103.67M | 232.26M | 468.04M | 569.55M | 923.68M |
| Depreciation & Amortization | 3.46M | 9.45M | 10.17M | 15.85M | 24.86M |
| EBITDA | (96.61M) | (214.03M) | (392.1M) | (448.08M) | (741.77M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (103.67M) | (232.26M) | (468.04M) | (569.55M) | (923.68M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 344K | 8.36M | 62.91M | 109.99M | 119.72M |
| Interest Expense | 7K | 2K | 0 | 0 | 0 |
| Other Income / Expenses | 3.59M | 8.77M | 65.78M | 105.62M | 157.05M |
| Income Before Tax | (100.08M) | (223.49M) | (402.27M) | (463.93M) | (766.63M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.08M) | (223.49M) | (402.27M) | (463.93M) | (766.63M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.93) | (3.44) | (4.14) | (3.80) | (5.63) |
| EPS (Diluted) | (1.93) | (3.44) | (4.14) | (3.80) | (5.63) |
| Weighted Avg Shares | 51.92M | 64.88M | 97.16M | 122M | 136.09M |
| Weighted Avg Shares (Diluted) | 51.92M | 64.88M | 97.16M | 122M | 136.09M |
Vaxcyte, Inc.
NASDAQ:PCVX
Intrinsic Alpha fair value
Locked
Current Price
$58.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.